Generated by AI
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for diseases with significant unmet medical needs. The company’s current pipeline centers on endocrine and neurodegenerative disorders, with avexitide as its lead investigational program. Avexitide is being studied as a first-in-class GLP-1 receptor antagonist for conditions linked to excessive insulin activity, including post-bariatric hypoglycemia and congenital hyperinsulinism. Amylyx also advances additional investigational therapies across other rare and serious diseases, reflecting a research portfolio built around well-defined biological targets and measurable clinical outcomes. Headquartered in Cambridge, Massachusetts, Amylyx Pharmaceuticals plays a role in the biotechnology market as a developer of targeted treatments for patients facing limited therapeutic options.
Website55 Cambridge Parkway
Cambridge, MA, 02142
United States
The latest articles about AMLX.
2026-11-18. The following slide deck was published by Amylyx Pharmaceuticals, Inc.
2026-11-15. The following slide deck was published by Amylyx Pharmaceuticals, Inc.
Summary of Aug 21's posts. Generated by AI.
Summary of Aug 19's posts. Generated by AI.
Summary of Feb 1's posts. Generated by AI.
Summary of Aug 21's posts. Generated by AI.
Investors talking about AMLX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.